Why the study?
In 50-60% of recurrent pregnancy loss cases, the cause remains unclear, motivating a comparison of maternal and fetal outcomes with empirical LMWH (enoxaparin) versus aspirin during pregnancy.
Does enoxaparin improve maternal and fetal outcomes compared to low dose aspirin in women with unexplained recurrent pregnancy loss?
Population
146 women aged 18-40 years with 3 or more pregnancy losses
Comparison
Enoxaparin vs aspirin during pregnancy
Follow-up
6 months after delivery
Authors
Loading...
May support enoxaparin after aspirin failure; hypothesis-generating and requires RCTs before practice change.
Does enoxaparin improve maternal and fetal outcomes compared to low dose aspirin in women with unexplained recurrent pregnancy loss?
Empirical use of enoxaparin may be beneficial as a first-line agent in women with unexplained recurrent pregnancy loss who have previously failed low-dose aspirin therapy.
Juneja et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: